Atea Pharmaceuticals, Inc. cotiza a 5.03 USD y tiene una capitalización bursátil de $403M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Ph…
| Periodo | 2026-03 | 2025-11 | 2025-08 | 2025-05 |
|---|---|---|---|---|
| Real | $-0.57 | $-0.53 | $-0.44 | $-0.40 |
| Estimado | $-0.48 | $-0.41 | $-0.41 | $-0.41 |
| Sorpresa | -18.7% | -29.3% | -7.3% | +2.4% |
| Métrica | AVIR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -57.5% | -40.4% | -17.1% |
| ROA | -50.2% | -32.0% | -18.2% |
| Current Ratio | 7.82 | 2.84 | +4.98 |
| Debt / Equity | — | 0.28 | — |